Immunogen (IMGN) Reports Q4 Loss of $0.17/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Financial Fact:
Clinical materials reimbursement: 46K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Clinical materials reimbursement: 46K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.17), versus $0.16 reported last year. Revenue for the quarter came in at $28 million, versus $85.8 million reported last year.
GUIDANCE:
Immunogen sees 2022 revenue of $75-85 million.
- revenues between $75 million and $85 million;
- operating expenses between $285 million and $295 million; and
- cash and cash equivalents at December 31, 2022, to be between $245 million and $255 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
